Clinical trials: Blood Protein Disorders
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed [ND]…
- Trial name
- NCT02761187
- Testing
- No Intervention
- Where
- 137 sites in United States, Belgium and 13 more
- Volunteers
- 4,253 people
- Sponsor
- Takeda
Myeloma
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
The goal of this clinical research study is to find the highest tolerable dose of Siltuximab that can be given in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
- Trial name
- NCT01531998
- Testing
- Lenalidomide, Bortezomib, Siltuximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
This study will test whether a plant-based diet is practical (feasible) for overweight people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM).
- Trial name
- NCT04920084
- Testing
- Plant based meals
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hemophilia B
Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects
This study will evaluate the safety and efficacy of on-demand treatment with BeneFIX in Chinese hemophilia B subjects.
- Trial name
- NCT00866606
- Testing
- Benefix
- Where
- 6 sites in China
- Volunteers
- 35 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Metastatic Cancers, Multiple Myeloma
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
Vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.
- Conditions
- Metastatic Cancers, Multiple Myeloma, Vertebral Fracture
- Trial name
- NCT02376933
- Testing
- Vertebroplasty, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Arizona
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Cancer-related Problem/Condition, Depression
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization.
- Conditions
- Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
- Trial name
- PEI (NCT03198754)
- Testing
- PEI Experimental Light, Comparison Light
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00975975
- Testing
- Basiliximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Hemophilia B
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children who have previously received factor replacement therapy for hemophilia B.
- Trial name
- NCT01662531
- Testing
- rIX-FP
- Where
- 17 sites in Australia, Austria and 8 more
- Volunteers
- 27 people
- Sponsor
- CSL Behring
Hematologic Disease, Hemophilia A
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule…
- Trial name
- NCT00586521
- Testing
- Kogenate (BAY14-2222)
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Bayer
Multiple Myeloma
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
- Trial name
- NCT05347485
- Testing
- Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- Where
- 18 sites in United States
- Volunteers
- 86 people
- Sponsor
- Janssen Scientific Affairs, LLC
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
The primary objective is to demonstrate the bioequivalence of Gammaplex® 10 intravenous immunoglobulin (IGIV) and Gammaplex® 5% IGIV with respect to area under the curve within a 28-day dosing interval (AUC0-28) in a cohort of…
- Conditions
- Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyper-IgM Syndrome
- Trial name
- GMX07 (NCT01963143)
- Testing
- Gammaplex (5%), Gammaplex 10
- Where
- 17 sites in United States, Hungary and 1 more
- Volunteers
- 48 people
- Sponsor
- Bio Products Laboratory
Severe Hemophilia A
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.
- Trial name
- NCT01992549
- Testing
- Human-cl rhFVIII
- Where
- 15 sites in United States, Canada and 7 more
- Volunteers
- 48 people
- Sponsor
- Octapharma
Hemophilia A
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
The goal of this study is to give gather more information on how safe and well Jivi works in patients with severe hemophilia A. Jivi has been approved by various regulatory agencies, including the FDA, Health Canada, Japanese…
- Trial name
- NCT04085458
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- 13 sites in Bulgaria, Denmark and 5 more
- Volunteers
- 32 people
- Sponsor
- Bayer
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Multiple Myeloma
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the antitumor efficacy and safety of bendamustine (SyB L-0501: 90 mg/m^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration for 2 consecutive days and 26-day observation…
- Trial name
- NCT01849848
- Testing
- SyB L-0501
- Where
- 14 sites in Japan
- Volunteers
- 17 people
- Sponsor
- SymBio Pharmaceuticals
Graft Versus Host Disease, Leukemia
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00577278
- Testing
- rituximab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Severe Haemophilia A
Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand…
- Trial name
- NCT01863758
- Testing
- Human-cl rhFVIII
- Where
- 20 sites in Austria, Bulgaria and 6 more
- Volunteers
- 66 people
- Sponsor
- Octapharma
Diabetes Mellitus, Impaired Fasting Glucose
Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c
Prevention of complications in veterans with diabetes depends heavily on assessment of blood glucose and HbA1c. The HbA1c is a blood test that measures the exposure of hemoglobin (Hb) to a person's average blood glucose over the…
- Conditions
- Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
- Trial name
- NCT01204216
- Testing
- re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.